SCHEMBL5808446

SCHEMBL5808446

Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCOC(=O)C(N)C(C)C)CC2)n1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 11/20 0.77
SRC P12931 8/20 0.77
LCK P06239 4/20 0.76
DDR1 Q08345 3/20 0.76
DDR2 Q16832 3/20 0.76
PKMYT1 Q99640 3/20 0.76
EPHB6 O15197 2/20 0.76
EGFR P00533 2/20 0.76
FYN P06241 2/20 0.76
CSF1R P07333 2/20 0.76
YES1 P07947 2/20 0.76
LYN P07948 2/20 0.76
RET P07949 2/20 0.76
HCK P08631 2/20 0.76
KIT P10721 2/20 0.76
BCR P11274 2/20 0.76
BRAF P15056 2/20 0.76
EPHA1 P21709 2/20 0.76
EPHA2 P29317 2/20 0.76
EPHA3 P29320 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5808441 1.00 ABL1 (0.77) ABL1SRCLCKDDR1DDR2
SCHEMBL793188 1.00 ABL1 (0.77) ABL1SRCLCKDDR1DDR2
SCHEMBL17347934 0.95 ABL1 (0.79) ABL1SRCLCKDDR1DDR2
SCHEMBL792953 0.92 ABL1 (0.76) ABL1SRCLCKDDR1DDR2
SCHEMBL16219601 0.92 ABL1 (0.76) ABL1SRCLCKDDR1DDR2
SCHEMBL17367319 0.91 ABL1 (0.78) ABL1SRCLCKDDR1DDR2
SCHEMBL28436547 0.91 ABL1 (0.82) ABL1SRCLCKDDR1DDR2
SCHEMBL5945218 0.90 ABL1 (0.77) ABL1SRCLCKDDR1DDR2
SCHEMBL17348011 0.90 ABL1 (0.82) ABL1SRCLCKDDR1DDR2
SCHEMBL17278262 0.90 ABL1 (0.81) ABL1SRCLCKDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9700633-B2 Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof JENKEM TECHNOLOGY CO., LTD., TIANJIN BRANCH (CN) 2017-07-11 US disclosed
US-20150359900-A1 CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF JENKEM TECHNOLOGY CO. LTD., TIANJIN BRANCH (CN) 2015-12-17 US disclosed
WO-2006037032-A2 PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-06 WO disclosed
US-20060069101-A1 Prodrugs of protein tyrosine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069101-A1 Prodrugs of protein tyrosine kinase inhibitors ABL1, LCK, BRAF ABL1 1/4885SRC 4/4885LCK 2/4885
US-20150359900-A1 CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF SLC7A1, NPPA, PEPD ABL1 1982/4885SRC 4644/4885LCK 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.